Non-Medical Switching Impact on Patients and Providers – Psoriatic Disease Community Taking a Stand

Abstract

Keywords

psoriasis psoriatic arthritis health policy insurance biologics chronic disease systemic disease management

Get full access to this article

View all access options for this article.

References

Kamata

Tada

. Efficacy and safety of biologics for psoriasis and psoriatic arthritis and their impact on comorbidities: a literature review. Int J Mol Sci. 2020;21(5):1690. Published 2020 Mar 1. doi:10.3390/ijms21051690

Wolf

Skup

Yang

, et al. Clinical outcomes associated with switching or discontinuation from anti-TNF inhibitors for nonmedical reasons. Clin Ther. 2017;39(4):849–862.e6. doi:10.1016/j.clinthera.2017.03.005

Teeple

Ginsburg

Howard

, et al. Patient attitudes about non-medical switching to biosimilars: results from an online patient survey in the United States. Curr Med Res Opin. 2019;35(4):603–609. doi:10.1080/03007995.2018.1560221